Skip to main content
. 2017 Jan 21;22(1):167. doi: 10.3390/molecules22010167

Table 2.

Determination of HF anticlastogenic effect towards cisplatin using the chromosome aberration test on HepG2 and VH10 cells.

HF/cisPt Concentration (µM) Number of Aberrant Metaphases Number of Chromosome Aberrations Total Number of CA
Chromatid Isochromatid Exchange
g b/f g b/f ring dic qr tr dmin
HepG2
IC 2 1 2 1 - - - - - - 2
SC 3 1 2 - - - 1 - - - 3
HF 0.75 1 1 1 - - - - - - - 1
HF 1.5 3 - 2 - 1 - - - - - 3
PC cisPt 0.5 38 *** 2 36 - 8 - 2 1 - - 47 ***
HF 0.75+ cisPt 0.5 10 *,### 2 5 - 4 - 2 - - - 11 *,###
HF 1.5 + cisPt 0.5 14 **,### 2 10 - 3 - 1 - - - 14 **,###
VH10
IC 2 - 2 - - - - - - - 2
SC 2 1 1 1 - - 1 - - - 2
HF 0.75 1 - 1 - - - - - - - 1
HF 1.5 1 - - - - - 1 - - - 1
PC cisPt 0.75 33 *** 2 26 - 9 - - 4 5 - 44 ***
HF 0.75 + cisPt 0.75 12 **,### 1 8 - 3 - 1 1 1 - 14 ***,###
HF 1.5 + cisPt 0.75 11 **,### 3 8 - - - 1 - 2 - 11 **,###

IC—intact control; SC—solvent control (PBS); HF—hyperforin; PC cisPt—positive control (cisplatin); CA—chromosome aberrations; g—gap; b/f—break and/or fragment; dic—dicentric; qr—quadriradial; tr—triradial. Comparison with solvent control (SC): * 0.01 < p < 0.05; ** 0.001 < p < 0.01; *** p < 0.001. Comparison with positive control (PC): ###p < 0.001.